English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

TO THE EDITOR—We read with interest the article by Fisher and colleagues about use of the galactomannan index (GMI) in hematopoietic stem cell transplant (HSCT) recipients with invasive aspergillosis (IA) [1]. The authors reported that the serum GM level at the time of IA diagnosis was significantly associated with the risk of overall and respiratory mortality. In their cohort, GM testing was performed upon clinical suspicion of IA; at our center, GM screening has been used even before clinical suspicion. Briefly, patients are tested at least twice weekly during the first 100 days after transplant or later in case of graft versus host

clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)

Screening With Serum Galactomannan Might Be Associated With Better Outcome Than Symptom-Triggered Galactomannan Testing in Allogeneic HSCT Recipients With Invasive Aspergillosis